Taysha Gene Therapies to Host Virtual R&D Day on Lead Clinical Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome
June 15 2023 - 8:00AM
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage
gene therapy company focused on developing and commercializing
AAV-based gene therapies for the treatment of monogenic diseases of
the central nervous system (CNS), today announced it will host a
virtual R&D Day on Wednesday, June 28, 2023 at 10:00 AM ET to
discuss updates on TSHA-120, a self-complimentary intrathecally
delivered investigational AAV9 gene therapy in clinical evaluation
for GAN, and TSHA-102, a self-complementary intrathecally delivered
AAV9 investigational gene transfer therapy in clinical evaluation
for Rett syndrome.
The event will feature collaborator Salman Bhai, MD, Assistant
Professor of Neurology at UT Southwestern Medical Center, who will
discuss the disease course and biology of GAN and present new data
and analyses from the ongoing natural history and interventional
trial evaluating TSHA-120. In addition, Taysha leadership will
provide a clinical update on the investigational TSHA-102 program,
including the initial safety observations of TSHA-102 from the
first patient recently dosed in the Phase 1/2 REVEAL trial. The
REVEAL trial is evaluating the safety and preliminary efficacy of
TSHA-102 in adult females with Rett syndrome. More detailed
clinical updates on the first patient will be provided in the third
quarter of this year following the initial review of available
safety data by the Independent Data Monitoring Committee.
A live question and answer session will follow the formal
presentations. To register for the event, please click here.
About Salman Bhai, MDDr. Bhai is an Assistant
Professor in the Department of Neurology at UT Southwestern Medical
Center and the Director of the Neuromuscular Center in the
Institute for Exercise and Environmental Medicine at Texas Health
Presbyterian Hospital Dallas. He specializes in neuromuscular
disorders. Dr. Bhai earned his medical degree at Harvard Medical
School. He completed his residency in neurology through Harvard
Medical School at Brigham and Women’s Hospital and Massachusetts
General Hospital, where he also received advanced training through
a fellowship in neuromuscular medicine and earned a medical
education certificate. He is board certified by the American Board
of Psychiatry and Neurology in neurology and neuromuscular medicine
as well as by the American Board of Electrodiagnostic Medicine. He
joined the UT Southwestern faculty in 2020. He is a member of the
American Academy of Neurology, the Dallas County Medical Society,
and the Texas Neurological Society. Dr. Bhai’s clinical interests
include the evaluation and treatment of neuromuscular disorders. He
focuses on patients with hereditary and autoimmune neuromuscular
disorders. Dr. Bhai’s research focuses on understanding metabolic
and mitochondrial dysfunction in muscle disorders. He is the
principal investigator for multiple clinical trials in
neuromuscular diseases. He serves as an organizer and a participant
for European Neuromuscular Center expert workshops. He has been an
invited lecturer nationally and internationally in his areas of
expertise. As a clinician-scientist and educator, Dr. Bhai strives
to improve the lives of patients and their families.
About Taysha Gene TherapiesTaysha Gene
Therapies (Nasdaq: TSHA) is on a mission to eradicate
monogenic CNS disease. With a singular focus on developing curative
medicines, we aim to rapidly translate our treatments from bench to
bedside. We have combined our team’s proven experience in gene
therapy drug development and commercialization with the world-class
UT Southwestern Gene Therapy Program. Together, we leverage our
fully integrated platform with a goal of dramatically improving
patients’ lives. More information is available
at www.tayshagtx.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as
“anticipates,” “believes,” “expects,” “intends,” “projects,”
“plans,” and “future” or similar expressions are intended to
identify forward-looking statements. Forward-looking statements
include statements concerning the potential of our product
candidates, including TSHA-120 and TSHA-102, to positively impact
quality of life and alter the course of disease in the patients we
seek to treat, our research, development and regulatory plans for
our product candidates, the potential for these product candidates
to receive regulatory approval from the FDA or equivalent foreign
regulatory agencies, and whether, if approved, these product
candidates will be successfully distributed and marketed and the
potential market opportunity for these product candidates.
Forward-looking statements are based on management’s current
expectations and are subject to various risks and uncertainties
that could cause actual results to differ materially and adversely
from those expressed or implied by such forward-looking statements.
Accordingly, these forward-looking statements do not constitute
guarantees of future performance, and you are cautioned not to
place undue reliance on these forward-looking statements. Risks
regarding our business are described in detail in
our Securities and Exchange Commission (“SEC”) filings,
including in our Annual Report on Form 10-K for the full-year
ended December 31, 2022, which is available on the SEC’s
website at www.sec.gov. Additional information will be made
available in other filings that we make from time to time with
the SEC. Such risks may be amplified by the impacts of the
COVID-19 pandemic. These forward-looking statements speak only as
of the date hereof, and we disclaim any obligation to update these
statements except as may be required by law.
Company Contact:Hayleigh CollinsDirector, Head
of Corporate CommunicationsTaysha Gene Therapies,
Inc.hcollins@tayshagtx.com
Media Contact:Carolyn HawleyCanale
Communicationscarolyn.hawley@canalecomm.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jul 2023 to Jul 2024